Komori
Human Metabolome Technologies (6090) · InitiativeFirst stated

Development and provision of mid-sized molecule metabolomics services

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Development and provision of middle-molecule metabolomics analysis servicesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「We are developing proprietary technology that enables comprehensive analysis of medium-sized molecules, whose molecular weights are between those of low-molecular-weight compounds, such as metabolites, and high-molecular-weight compounds, such as proteins, and will offer it as a medium-molecule metabolomics service.」

    The company first explicitly stated a plan to develop proprietary analytical technologies covering the intermediate field between small and large molecules and provide them as a new service for drug discovery research, novel biomarker discovery and functional substance discovery.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development and provision of mid-sized molecule metabolomics services | Human Metabolome Technologies,Inc. (6090) | Komori